Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Activity and Toxicity Profile of Eribulin Mesylate in Pretreated Metastatic Breast Cancer: an Observational Multicentric Retroprospective Study

NCT02393287 is registered in ClinicalTrials.gov with Institut Cancerologie de l'Ouest as lead sponsor.

NCT NCT02393287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02393287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Activity and Toxicity Profile of Eribulin Mesylate in Pretreated Metastatic Breast Cancer: an Observational Multicentric Retroprospective Study
Lead sponsor
Institut Cancerologie de l'Ouest
Phase
Observational
Overall status
Completed
Start date
November 30, 2014
Completion date
January 31, 2017
Enrollment
753 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer